Startups
We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.
Overview
Location
United States, California, Brisbane
Employees
201-500
Total raised
$218M
Founded date
2016
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 20
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 24, 2022 | Myovant Sciences Accepts Sweetened $2.9 Billion Bid From Sumitomo Pharma | Myovant Sciences stock rose sharply on Monday after a subsidiary of Japan’s Sumitomo Pharma said it would purchase the rest of the drugmaker at an improved price of $27 per share. Myovant Sciences (ticker: MYOV), which creates treatments fo... |
| Jan 31, 2022 | Sumitomo Dainippon Pharma : Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022 (PDF/305KB) | Securities Code: 4506 Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022 I. Consolidated Financial Highlights 1 II. Consolidated Statement of Profit or Loss 3 III. Segment Information 4 IV. Revenues ... |
| Jan 31, 2022 | Sumitomo Dainippon Pharma : Jan. 31, 2022 Q3 FY2021 Conference Call(PDF/1,158KB) | Q3 FY2021 (April 1 to December 31, 2021） Conference Call January 31, 2022 Sumitomo Dainippon Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, targets, plans, and other forward-l... |
| Jan 31, 2022 | Sumitomo Dainippon Pharma : Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022 | Securities Code: 4506 Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022 I. Consolidated Financial Highlights 1 II. Consolidated Statement of Profit or Loss 3 III. Segment Information 4 IV. Revenues ... |
| Jan 31, 2022 | Sumitomo Dainippon Pharma : Q3 FY2021 (April 1 to December 31, 2021） Conference Call | Q3 FY2021 (April 1 to December 31, 2021） Conference Call January 31, 2022 Sumitomo Dainippon Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, targets, plans, and other forward-l... |
| Dec 8, 2021 | Sumitomo Dainippon Pharma : Dec. 08, 2021 ESG Meeting (Discussion with Investors)(PDF/2,718KB) | ESG Meeting (Discussion with Investors) December 8, 2021 Sumitomo Dainippon Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, targets, plans, and other forward-looking statements... |
| Dec 8, 2021 | Sumitomo Dainippon Pharma : ESG Meeting (Discussion with Investors) | ESG Meeting (Discussion with Investors) December 8, 2021 Sumitomo Dainippon Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, targets, plans, and other forward-looking statements... |
| Nov 9, 2021 | Oct. 28, 2021 Investors Meeting Presentation for Q2 FY2021 transcript(PDF/2,389KB) | Summary of Investors Meeting for Q2 FY2021 [Date] October 28, 2021 10:30 ‐ 11:33 (Total: 63 minutes, Presentation: 18 minutes, Q&A: 45 minutes) [Venue] Live stream and conference call [Number of Speakers] 3 Hiroshi Nomura Representative... |
| Oct 27, 2021 | Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2022 (PDF/534KB) | Securities Code: 4506 Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2022 I. Consolidated Financial Highlights 1 II. Consolidated Statement of Profit or Loss 3 III. Segment Information 4 IV. Revenues... |
Show more
Reviews 0
FAQ about Myovant Sciences
When was Myovant Sciences founded?
Myovant Sciences was founded in 2016.
How much funding has Myovant Sciences raised?
Myovant Sciences has raised $218M in total across 1 funding round.
What has the press written about Myovant Sciences?
Parsers VC has collected 20 articles mentioning Myovant Sciences, among them “Myovant Sciences Accepts Sweetened $2.9 Billion Bid From Sumitomo Pharma” (Oct 24, 2022) and “Sumitomo Dainippon Pharma : Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022 (PDF/305KB)” (Jan 31, 2022).
Is Myovant Sciences still active?
Yes, Myovant Sciences is active; its latest activity on Parsers VC dates from Jun 29, 2026.